Cook ends Johnson & Johnson's drug-coated stent reign in the EU
This article was originally published in Clinica
Executive Summary
In a move that finally marks the end of Johnson & Johnson's monopoly of the European drug-coated coronary stent market, rival firm Cook has CE-marked for sale its paclitaxel-coated V-Flex Plus PTX stent.